PALO ALTO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time to all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH) in both variant (ATTRv) and wild-type (ATTRwt) transthyretin amyloid cardiomyopathy (ATTR-CM) patients from a pre ...

Core Viewpoint - BridgeBio Pharma has received approval from the Japanese Ministry of Health for acoramidis, branded as Beyonttra, to treat adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), marking a significant advancement in treatment options for this progressive and fatal disease [1][2]. Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing treatments for genetic diseases, founded in 2015. The company aims to deliver transformative medicines through a pipeline that includes early science to advanced clinical trials [9]. Product Details - Acoramidis is a selective small molecule, orally administered, and is a near-complete (≥90%) stabilizer of transthyretin (TTR). It has shown potential in reducing all-cause and cardiovascular mortality risks [1][6]. - The drug was well-tolerated in clinical trials, with a reported 0% mortality during a 30-month treatment period in the Japanese Phase 3 study [3][8]. Clinical Trial Results - The approval in Japan was based on positive outcomes from a Phase 3 open-label study and the global ATTRibute-CM Phase 3 trial. Key findings include: - Early separation in time to first event (all-cause mortality or cardiovascular-related hospitalization) at 3 months compared to placebo [3][8]. - A 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalization events at Month 30 relative to placebo [3][8]. - A 50% reduction in cumulative frequency of cardiovascular hospitalization events at Month 30 compared to placebo [3][8]. Commercialization and Financials - Alexion, AstraZeneca Rare Disease holds an exclusive license to develop and commercialize acoramidis in Japan. BridgeBio will receive a $30 million milestone payment upon approval and low double-digit royalties on sales [4][8].

Core Insights - BridgeBio Pharma announced the presentation of cardiovascular outcomes data from its Phase 3 study of acoramidis in patients with ATTR-CM at the ACC Annual Scientific Sessions & Expo in March 2025 [1] Group 1: Presentation Details - Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy [2] - Acoramidis improves NYHA class at month 30 versus placebo in patients with ATTR-CM [2] - Addition of concomitant tafamidis did not further increase serum TTR levels in participants treated with acoramidis [3] - Efficacy results of acoramidis in ATTR-CM were robust according to pre-specified NT-proBNP sensitivity analyses [3] - Acoramidis-mediated early increase in serum transthyretin level reduces cardiovascular-related hospitalizations and mortality [3] Group 2: Moderated Posters - Primary endpoint efficacy results in the ATTRibute-CM study addressed tafamidis use [4] - Geographic healthcare disparities and diagnostic trends among patients with transthyretin amyloid cardiomyopathy [4] Group 3: Product Information - Attruby (acoramidis) is the first near-complete stabilizer of TTR approved in the U.S. for treating ATTR-CM in adults [5] - Attruby aims to reduce cardiovascular death and related hospitalizations and was generally well-tolerated with mild side effects [5] Group 4: Company Overview - BridgeBio Pharma focuses on discovering, creating, testing, and delivering transformative medicines for genetic diseases [6] - The company was founded in 2015 and has a pipeline ranging from early science to advanced clinical trials [6]

PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company. He recently assumed the role of Principal Financial Officer and will continue to lead the Company’s FP&A and accounting operations. Brian Stephenson, Ph.D. will depart from the Company for personal rea ...

Our Purpose: To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. ...

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturityOffering priced at 1.75% interest rate and 45% conversion premium PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified ...

Core Viewpoint - BridgeBio Pharma, Inc. plans to offer $500 million of convertible senior notes due 2031 to strengthen its balance sheet and manage long-term debt without increasing total liabilities [1][2] Group 1: Offering Details - The company intends to offer $500 million aggregate principal amount of convertible senior notes due 2031, with an option for initial purchasers to buy an additional $75 million [1] - The notes will bear interest semi-annually and will mature on March 1, 2031, with specific conditions for conversion prior to December 2, 2030 [4] - The final terms, including conversion rate and interest rate, will be determined at the time of pricing [4] Group 2: Use of Proceeds - A portion of the net proceeds will be used to repay all outstanding borrowings under a Financing Agreement, which accounted for approximately $51.5 million in interest paid in 2024 [2] - Up to $50 million of remaining net proceeds will be used for share repurchases of common stock from certain purchasers of the notes [2] - Any remaining net proceeds will be allocated for general corporate purposes [2] Group 3: Debt Management Strategy - The refinancing of the term debt facility is expected to lower interest expenses, eliminate near-term amortization payments, and significantly extend debt maturity [1] - The notes will rank senior in right of payment to any unsecured indebtedness that is subordinated and will be effectively junior to secured indebtedness [6] Group 4: Market Impact - Share repurchases could influence the market price of the company's common stock and potentially result in a higher effective conversion price for the notes [3] - The company cannot predict the magnitude of market activity or its overall effect on the market price of the notes or common stock [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38959 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) | Delaware | 84-1850815 | | --- | --- | | State or o ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Shares of BridgeBio (NASDAQ: BBIO ) are nearing 52-week highs following the fourth quarte ...

Company Performance - BridgeBio Pharma reported a quarterly loss of $1.31 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.09, and compared to a loss of $0.96 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $5.88 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 10.98%, and showing a substantial increase from year-ago revenues of $1.75 million [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - The stock has gained approximately 32.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.89 on revenues of $41.63 million, and for the current fiscal year, it is -$3.66 on revenues of $223.42 million [7] - The estimate revisions trend for BridgeBio Pharma is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment and stock performance [5]